| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 05/04/2004 | US6730299 Kit; simple, practical; bioresorbable, nontoxic wound protection; biocompatible fluid and gas; produces foam |
| 05/04/2004 | US6730296 Receptor agonists and antagonists |
| 05/04/2004 | CA2296178C Human intestinal npt2b |
| 05/04/2004 | CA2278057C Tachykinin antagonists |
| 05/04/2004 | CA2240296C Endothelial cell proliferation inhibitor and method of use |
| 05/04/2004 | CA2110442C Process for obtaining proinsulin possessing correctly linked cystine bridges |
| 05/04/2004 | CA2080226C Cd4-gamma2 and cd4-igg2 chimeras |
| 04/30/2004 | CA2450643A1 Methods of diagnosing, preventing, and treating early onset of pulmonary hypertension |
| 04/29/2004 | WO2004036186A2 Microencapsulation and sustained release of biologically active polypeptides |
| 04/29/2004 | WO2004035802A1 Protein modification |
| 04/29/2004 | WO2004035798A2 Identification of e2f target genes and uses thereof |
| 04/29/2004 | WO2004035789A1 Gene families associated with cancers |
| 04/29/2004 | WO2004035786A1 A method of modulating epithelial cell activity by modulating the functional levels of sphingosine kinase |
| 04/29/2004 | WO2004035777A1 Adipocyte differentiation-associated genes and proteins |
| 04/29/2004 | WO2004035769A1 Improved immunotherapy |
| 04/29/2004 | WO2004035763A2 Antisense modulation of gfat expression |
| 04/29/2004 | WO2004035762A2 Microencapsulation and sustained release of biologically active polypeptides |
| 04/29/2004 | WO2004035758A2 Rna-based inhibitory oligonucleotides |
| 04/29/2004 | WO2004035755A2 Transporters and ion channels |
| 04/29/2004 | WO2004035754A2 Microencapsulation and sustained release of biologically active polypeptides |
| 04/29/2004 | WO2004035741A2 Susceptibility gene for myocardial infarction; methods of treatment |
| 04/29/2004 | WO2004035729A2 Esterases, nucleic acids encoding them and methods of making and using them |
| 04/29/2004 | WO2004035627A1 Modulation of tgfbeta-like signalling pathways |
| 04/29/2004 | WO2004035624A2 Glucagon - like peptide - 2 variants |
| 04/29/2004 | WO2004035623A2 Stabilized exendin-4 compounds |
| 04/29/2004 | WO2004035615A2 Factor involved in metastasis and uses thereof |
| 04/29/2004 | WO2004035613A2 4-methylhexanoic kahalaide f compound |
| 04/29/2004 | WO2004035611A2 Peptides binding the phosphatase 2a protein and polynucleotides encoding same |
| 04/29/2004 | WO2004035609A2 Use of poly-alpha2,8-sialic acid mimetic peptides to modulate ncam functions. |
| 04/29/2004 | WO2004035605A2 Glycoprotein synthesis |
| 04/29/2004 | WO2004035536A2 Azo compounds for type i phototherapy |
| 04/29/2004 | WO2004035535A2 Erythrocyte differentiation factor, gene encoding same, and methods of use thereof |
| 04/29/2004 | WO2004035139A1 Regulation of mkk3 |
| 04/29/2004 | WO2004035086A2 Method for treatment of demyelinating central nervous system disease using gm-csf |
| 04/29/2004 | WO2004035083A2 Compositions for the treatment of autoimmune disorders |
| 04/29/2004 | WO2004035082A2 Proteins involved in the regulation of energy homeostasis |
| 04/29/2004 | WO2004035081A1 Activity of osteogenic growth peptide (ogp) for promoting proliferation of hemopoietic progenitor cell in erythron and its use |
| 04/29/2004 | WO2004035080A1 Treatment of hypersensitivity conditions |
| 04/29/2004 | WO2004035079A1 Treatment of osteoarthritis |
| 04/29/2004 | WO2004035078A1 Treatment of inflammatory bowel disease |
| 04/29/2004 | WO2004035076A1 Treatment of tnf-alpha-mediated disorders with casein kinase i epsilon inhibitors |
| 04/29/2004 | WO2004035069A1 Pharmaceutical antidiabetic composition |
| 04/29/2004 | WO2004035067A1 Method for extracting a natural mixture of conjugated equine estrogens that is depleted of non-conjugated lipophilic compounds |
| 04/29/2004 | WO2004035021A2 Buccal polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system |
| 04/29/2004 | WO2004035011A2 Botulinum toxin dental therapies and procedures |
| 04/29/2004 | WO2004035008A2 Treatment of infections and other disorders |
| 04/29/2004 | WO2004035007A2 Transmucosal administration of aggregated antigens |
| 04/29/2004 | WO2004034995A2 Methods and reagents for inducing immunity |
| 04/29/2004 | WO2004034993A2 Methods of preventing morbidity and mortality by perioperative administration of a blood clotting inhibitor |
| 04/29/2004 | WO2004034977A2 Orally administered peptides synergize statin activity |
| 04/29/2004 | WO2004034975A2 Sustained release profile modification |
| 04/29/2004 | WO2004034973A2 Method of treating snoring and other obstructive breathing disorders |
| 04/29/2004 | WO2004034971A2 Methods for treating and preventing sepsis using modified c1 inhibitor or fragments thereof |
| 04/29/2004 | WO2004034966A2 Substances for preventing and treating autoimmune diseases |
| 04/29/2004 | WO2004034957A2 Methods for treatment of helicobacter pylori-associated disorders |
| 04/29/2004 | WO2004034813A2 Composition for reducing caloric intake |
| 04/29/2004 | WO2004034789A1 Methods of preparing lymphocytes that express interleukin-2 and their use in the treatment of cancer |
| 04/29/2004 | WO2004020979A9 Methods of assaying for cell cycle modulators using components of the ubiquitin ligation cascade |
| 04/29/2004 | WO2004020469A3 Ocular gene therapy |
| 04/29/2004 | WO2004016151A3 Pthrp-derived modulators of smooth muscle proliferation |
| 04/29/2004 | WO2004015107A3 Further novel forms of interfering rna molecules |
| 04/29/2004 | WO2004014943A3 Biphalin derivates and their analgesic applications |
| 04/29/2004 | WO2004012732A3 Use of a proteasome inhibitor in the treatment of endothelial dysfunction and/or in a low-dose proteasome inhibitor therapy |
| 04/29/2004 | WO2004007770A3 Method for diagnosis of intestinal-type gastric tumors |
| 04/29/2004 | WO2004005346A3 Human nuclear hormone receptor |
| 04/29/2004 | WO2004003185A3 Plant deoxyribonucleoside kinase enzymes and their use |
| 04/29/2004 | WO2004000993A3 Oxytocin as cardiomyogenesis inducer and uses thereof |
| 04/29/2004 | WO2003104485A3 Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue |
| 04/29/2004 | WO2003104282A8 Glycoprotein vi - fc fusion protein for treating vascular disorders |
| 04/29/2004 | WO2003097801A3 Cancer-linked gene as target for chemotherapy |
| 04/29/2004 | WO2003096869A3 Recombinant bet. v. 1. allergen mutants, methods and process thereof |
| 04/29/2004 | WO2003095487A3 Immunogenic cd1 complexes |
| 04/29/2004 | WO2003087408A3 Schizophrenia associated genes |
| 04/29/2004 | WO2003087368A3 Means and methods for the specific modulation of target genes in the cns and the eye and methods for their identification |
| 04/29/2004 | WO2003087367A3 Means and methods for the specific inhibition of genes in cells and tissue of the cns and/or eye |
| 04/29/2004 | WO2003072712A3 A novel protein for inhibiting tumor progression and increasing nerve regeneration |
| 04/29/2004 | WO2003065973A3 Multivalent streptococcal vaccine compositions and methods for use |
| 04/29/2004 | WO2003057223A9 Method of treating sexual dysfunctions with delta opioid receptor agonist compounds |
| 04/29/2004 | WO2003057134A3 Specific binding agents of human angiopoietin-2 |
| 04/29/2004 | WO2003048187A3 Peptides and use thereof in therapeutic agents against hiv infection |
| 04/29/2004 | WO2003042399A9 A nucleic acid encoding a g-protein-coupled receptor, and uses thereof |
| 04/29/2004 | WO2003038040A9 32235, a human aminotransferase family member and uses therefor |
| 04/29/2004 | WO2003032913A9 Methods and compositions for targeting proteins across the blood brain barrier |
| 04/29/2004 | WO2003025171A9 Modulation of retinoic acid receptor gene expression and therapeutic uses thereof |
| 04/29/2004 | WO2003020949A3 Targeted nucleic acid constructs and uses related thereto |
| 04/29/2004 | WO2003015612A9 Materials and methods to promote repair of nerve tissue |
| 04/29/2004 | WO2003013537A9 Irinotecan for treatment of cancer |
| 04/29/2004 | WO2003013536A9 Methods for treatment of cancer using irinotecan based on ugt1a1 |
| 04/29/2004 | WO2003013535A9 Use of irinotecan for improved treatment of cancer based on mdr1 |
| 04/29/2004 | WO2003013534A9 Methods for the treatment of cancer with irinotecan based on cyp3a5 |
| 04/29/2004 | WO2003013533A9 Methods for improved treatment of cancer with irinotecan based on mrp1 |
| 04/29/2004 | WO2003010196A3 Variants and exons of the glyt1 transporter |
| 04/29/2004 | WO2003004517A3 Peyers's patch and/or m-celle targeting ligands |
| 04/29/2004 | WO2003003004A3 Method for identifying compounds the specifically deplete mast cells |
| 04/29/2004 | WO2002088380A9 Immunogenic tumor antigens: nucleic acids and polypeptides encoding the same and methods of use thereof |
| 04/29/2004 | WO2002072630A3 Nucleic acid-associated proteins |
| 04/29/2004 | WO2002072612A3 Peptidic modulators of the androgen receptor |
| 04/29/2004 | WO2002070669A3 Secreted proteins |
| 04/29/2004 | WO2002043771A9 Conjugates of glycosylated/galactosylated peptide |
| 04/29/2004 | WO2002032941A8 The function of a haptoglobin-haemoglobin receptor and the uses thereof |